Website Details

* Please reduce the overall width of the website to provide a ~5-10% buffer zone on each side. Let me know if that looks right. The point is is that I don’t like the look of the site graphic going all the way to the edge. Let me know what you think.
* Logo- betastem is good. Make the therapeutics longer (a larger font) and wider with just “therapeutics”, not “inc.”

**Front Page-**

**Autologous Stem Cell Therapy for Diabetic Retinopathy**

We will utilize stem cells from one patient for that patient only. This will allow personalized medicine to be delivered to that patient without the risk of immune response to our patented cellular therapy. Learn about our therapy here.

**Opthalmologists working with BetaStem**

With more than 25,000 ophthalmologists in the United States, BetaStem will work with centers of excellence in ocular medicine to deliver our therapy to patients with the risk of vision loss from DR. Read how the treatment process will work here.

**Diabetic Retinopathy (DR)**

Diabetic retinopathy is the leading cause of adult blindness in the United States and other industrialized nations. The nearly early eight million Americans who have DR are also at risk of losing their vision to this progressive disease. Learn about DR here.

Vision- The BetaStem vision is to develop and commercialize the first curative treatment for patients suffering the devastating effects of diabetic Retinopathy

Mission- The BetaStem team will work together with, advisors, investors, the FDA and other international medical advisory panels to bring to market a safe, effective, cellular therapy for diabetic retinopathy.

Core Values

Strategic Areas of Focus

Strategic Goals

About BetaStem

**About BetaStem-**

**Overview**

**Values**

**Leadership**

**Management**

**You have this information**

**Scientific Advisory Board**

**Cellular Therapy Experts**

**Shelly Heimfeld, PhD—** Full Member, Head Human Cellular Therapy Laboratory and cGMP Cell Processing, Fred Hutchinson Cancer Research Center, Seattle, WA

**Francis W. “Frank” Ruscetti, PhD—** Principal Investigator, Leukocyte Biology Section, National Cancer Institute, NIH, MD (Retired)

**Eye Experts**

**Robert N. Frank, MD—** Professor, Kresge Eye Institute, Wayne State School of Medicine Detroit, MI

**Rudolph M. Franklin, MD—** Ophthalmologist, Specialist in Retina and Inflammatory Eye Diseases, La Place, LA

**Charles A. Garcia, MD—** Ophthalmologist and Professor, University of Texas Medical School, Houston, TX

**Thomas W. Gardner, MD—** Professor, Ophthalmology Kellogg Eye Center, Ann Arbor, MI

**Maria B. Grant, MD—** Marilyn Glick Professor of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, University of Indiana, Indianapolis, IN

**Gholam Peyman, MD—** Professor of Ophthalmology & Basic Medical Sciences, University of Arizona, Phoenix, AZ

**Board of Directors**

**Chairman, CEO**- Stephen Bartelmez, PhD

Discussions are underway with several of the world’s experts to join the Board